AstraZeneca is investing US$ 2 billion to expand its biologics manufacturing footprint in Maryland, including a major upgrade at its Frederick site and construction of a new clinical-manufacturing facility in Gaithersburg. The move will support around 2,600 jobs and bolster the U.S. medicines supply chain.
Glimpse:
The investment will nearly double commercial biologics capacity at the Frederick site and allow the production of rare disease therapies for the first time in the U.S. Meanwhile, a new facility in Gaithersburg will support clinical-stage manufacturing, generating hundreds of jobs and retaining existing roles.
Pharmaceutical giant AstraZeneca has announced a $2 billion investment to grow its Maryland manufacturing operations part of a broader U.S. push aligned with its $50 billion commitment to expand U.S. research and production capabilities.
At its Frederick facility, the investment will nearly double current capacity, enabling production of biologics used in cancer, autoimmune, respiratory, and rare disease treatments. The expansion is expected to create 200 highly skilled roles and about 900 construction jobs.
In Gaithersburg, AstraZeneca will build a state-of-the-art clinical manufacturing plant for development-stage molecules. The facility is projected to open by 2029, creating 100 new jobs, retaining 400 current jobs, and supporting around 1,000 construction jobs.
Both facilities will be built with advanced technologies AI, automation, and data analytics and adhere to high environmental standards.Maryland Governor Wes Moore welcomed the expansion as a key boost to the life sciences ecosystem and U.S. medicine supply chain resilience.
“As Maryland’s leading biopharma employer, we are deepening our commitment strengthening the U.S. medicine supply chain while bringing our rare disease portfolio onshore for the first time.” Pascal Soriot, CEO, AstraZeneca
By
HB Team
